Acadia Pharmaceuticals Inc.

Acadia Pharmacueticals Inc.

Mark R Brann

David M Weiner

Robert E Davis

Carl-Magnus A Andersson

Allan K Uldam

Niels Skjaerbaek

Tracy Spalding

Kate Duggento

Mikael Friberg

Norman Nash

Terri Messier

Erika Currier

Fabrice Piu

Ethan S Burstein

Daun Bahr

Daniel Van Kammen

Jakob L Hansen

Allan K Uldan

Andria Lee

Perry Peters

Anna-Maria Frost-Jensen, Legal Representative

David Furlano

MDavid Weiner

Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.

Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

Combinations of 5-HT2A inverse agonists or antagonists such as pimavanserin with antipsychotics such as risperidone are shown to induce a rapid onset of antipsychotic action and increase the number of responders when compared to therapy with the antipsychotic alone. These effects can be achieved at a low dose of the antipsychotic, thereby reducing the incidence of side effects. The combinations are also effective at decreases the incidence of weight gain and increased glucose or prolactin levels caused by the antipsychotic.

Combination of pimavanserin and risperidone for the treatment of psychosis

Disclosed herein are pharmaceutical compositions comprising an inverse serotonin receptor agonist or a serotonin receptor antagonist and an anti-psychotic agent. Disclosed herein are also methods of treating psychotic disorders using the disclosed pharmaceutical compositions.

Selective serotonin receptor inverse agonists as therapeutics for disease

Disclosed herein are pharmaceutical compositions comprising an inverse serotonin receptor agonist or a serotonin receptor antagonist and an anti-insomnia agent. Disclosed herein are also methods of treating insomnia using the disclosed pharmaceutical compositions.

Growing community of inventors

Rye, NH, United States of America

Mark R Brann